• 13F History

EQUITY INVESTMENT CORP

13F Filings History

Latest 13F report
Q4 2024 - Feb 5, 2025
Value $
$4.27B
Signature - Title
Phillip Lorren - Chief Compliance Officer
Location
Atlanta, GA
Summary
This page shows a list of all the recent 13F filings made by EQUITY INVESTMENT CORP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. EQUITY INVESTMENT CORP reported 63 stock holdings with total value $4.27B as of Q4 2024. Top holdings included T, WFC, VZ, PYPL, and KVUE.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q4 2024 63 $4.27B +$371M -$336M +$35.2M T, WFC, VZ, PYPL, KVUE 13F-HR 2/4/2025, 07:21 PM
Q3 2024 65 $4.3B +$215M -$173M +$41.4M T, VZ, SGOV, PYPL, KVUE 13F-HR 11/7/2024, 11:41 AM
Q2 2024 65 $3.92B +$212M -$140M +$72.6M T, VZ, SGOV, WFC, GSK 13F-HR 8/7/2024, 07:31 PM
Q1 2024 63 $4B +$472M -$302M +$169M VZ, SGOV, T, WFC, UL 13F-HR 5/6/2024, 09:47 PM
Q4 2023 60 $3.56B +$187M -$209M -$22.2M VZ, T, SGOV, WFC, GSK 13F-HR 2/8/2024, 05:28 PM
Q3 2023 62 $3.21B +$243M -$163M +$80.2M SGOV, T, GSK, VZ, TTE 13F-HR 11/7/2023, 08:29 PM
Q2 2023 60 $3.23B +$327M -$228M +$99.3M SGOV, VZ, GSK, WFC, T 13F-HR 8/2/2023, 06:47 PM
Q1 2023 57 $3.05B +$206M -$74.9M +$131M T, VZ, GSK, INGR, META 13F-HR 5/3/2023, 09:34 PM
Q4 2022 56 $2.97B +$279M -$59.9M +$219M T, TTE, VZ, INGR, GL 13F-HR 2/7/2023, 07:47 PM
Q3 2022 53 $2.61B +$298M -$72.8M +$225M T, GL, WFC, TTE, INGR 13F-HR 11/9/2022, 01:54 PM
Q2 2022 55 $2.7B +$309M -$209M +$100M GSKXXXX, T, VZ, TTE, INGR 13F-HR 8/8/2022, 04:36 PM
Q1 2022 58 $2.93B +$537M -$437M +$99.7M T, GSKXXXX, VZ, WMB, DLTR 13F-HR 5/10/2022, 03:06 PM
Q4 2021 53 $2.76B +$232M -$169M +$63.7M GSKXXXX, DLTR, VZ, WFC, GD 13F-HR 2/7/2022, 07:14 PM
Q3 2021 52 $2.61B +$61.7M -$91.2M -$29.6M GSKXXXX, VZ, WFC, GD, T 13F-HR 11/15/2021, 09:56 AM
Q2 2021 52 $2.66B +$216M -$190M +$26.7M GSKXXXX, VZ, WFC, WMB, AXP 13F-HR 8/6/2021, 11:15 AM
Q1 2021 51 $2.52B +$200M -$149M +$50.9M VZ, GSKXXXX, HIG, WFC, USB 13F-HR 5/12/2021, 03:12 PM
Q4 2020 50 $2.14B +$174M -$208M -$34M SCHW, GSKXXXX, VZ, HIG, USB 13F-HR 2/9/2021, 08:42 PM
Q3 2020 51 $1.96B +$200M -$270M -$70M UPS, VZ, JNJ, GSKXXXX, SCHW 13F-HR 11/12/2020, 04:23 PM
Q2 2020 49 $2.01B +$143M -$293M -$150M VZ, UPS, GSKXXXX, TFC, TRV 13F-HR 8/10/2020, 09:43 AM
Q1 2020 49 $1.94B +$333M -$465M -$131M VZ, UPS, JNJ, GSKXXXX, TRV 13F-HR 5/11/2020, 12:21 PM
Q4 2019 53 $2.91B +$242M -$172M +$69.5M SHV, GSKXXXX, USB, UPS, TFC 13F-HR 2/11/2020, 04:05 PM
Q3 2019 47 $2.8B +$200M -$253M -$52.9M SHV, UPS, GSKXXXX, USB, KR 13F-HR 11/12/2019, 08:32 AM
Q2 2019 62 $2.86B +$131M -$293M -$162M SHV, EBAY, USB, GSKXXXX, AXP 13F-HR 8/5/2019, 12:48 PM
Q1 2019 60 $2.96B +$247M -$203M +$43.5M SHV, GSKXXXX, UPS, XOM, EBAY 13F-HR 5/7/2019, 04:48 PM
Q4 2018 65 $2.77B +$292M -$257M +$35.8M SHV, VZ, GSKXXXX, USB, EXC 13F-HR 2/12/2019, 06:34 PM
Q3 2018 61 $3.1B +$235M -$340M -$106M SHV, XOM, GSKXXXX, TGT, AXP 13F-HR 11/5/2018, 03:49 PM
Q2 2018 56 $3.08B +$158M -$90.8M +$66.8M SHV, EXC, XOM, GSKXXXX, AXP 13F-HR 8/3/2018, 10:25 AM
Q1 2018 57 $3.01B +$485M -$344M +$141M SHV, GSKXXXX, EXC, XOM, USB 13F-HR 5/7/2018, 12:25 PM
Q4 2017 57 $3B +$104M -$212M -$108M EXC, EBAY, AXP, TGT, WFC 13F-HR 2/12/2018, 03:08 PM
Q3 2017 53 $2.9B +$83.3M -$194M -$111M EBAY, WMT, EXC, AXP, PNC 13F-HR 11/9/2017, 07:22 PM
Q2 2017 46 $2.93B +$93.9M -$299M -$205M WMT, EXC, EBAY, MDT, AXP 13F-HR 8/4/2017, 12:28 PM
Q1 2017 40 $3.07B +$243M -$246M -$3.11M EBAY, EXC, WMT, XOM, GSKXXXX 13F-HR 5/9/2017, 04:51 PM
Q4 2016 42 $3.11B WMT, EXC, PEP, XOM, EBAY 13F-HR 2/2/2017, 06:55 AM